Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 21st Preview)
-
Biopharma dealmaking and fundraising surge
Biopharma deal value hit a record first half as megadeals pushed total M&A proceeds to $170.11 billion through June 2026, according to BioWorld’s records. The haul surpassed prior yearly highs, with May and June delivering especially strong momentum. Alongside dealmaking, the IPO calendar also warmed: Parabilis priced the highest biopharma IPO on record at $670 million, while broader financing activity through the first half reached $60.14 billion—the strongest H1 since 2024. Investors and companies are now positioning transactions around clearer clinical differentiation and monetization paths, rather than pure platform potential.
-
Precision oncology diagnostics: Tempus to buy Personalis
Tempus AI agreed to acquire Personalis for $1.5 billion, extending its minimal residual disease (MRD) diagnostics footprint. Under the deal, Personalis shareholders will receive $16.25 per share in an about 6% premium, with closing expected in late 2026 or early 2027 subject to approvals. The acquisition builds on a 2023 partnership in which Tempus co-commercialized Personalis’ tumor-informed NeXT Personal MRD test. Tempus said combining Personalis sequencing technology with its multimodal data platform and AI capabilities is aimed at improving biomarker discovery and clinical adoption as reimbursement continues expanding. Personalis reported preliminary Q2 revenue of $22.4 million and delivery of 10,384 tests, up 33% quarter over quarter, underscoring demand as payers increase coverage of blood-based cancer monitoring.
-
Spatial and single-cell tools move deeper into clinical workflows
10x Genomics advanced its push from research platforms into clinical diagnostics by detailing plans for a CLIA-certified laboratory at its Pleasanton, California headquarters. The lab is expected to open next year, supporting clinical assay validation and enabling 10x to scale collaborations that use its single-cell sequencing and spatial biology platforms. The company also cited a multi-year collaboration with Cleveland Clinic focused on bladder cancer biomarkers, using patient samples to correlate single-cell and spatial findings with therapeutic outcomes across immunotherapies and antibody-drug conjugates. Separately, Parhelia Biosciences and Sirona Dx announced a partnership to improve scalability and reproducibility for spatial biology workflows. Parhelia will contribute its Spatial Station automation platform, while Sirona Dx will help tailor workflows across clients for discovery through clinical development.
-
Rare disease gene therapy: Broad launches Center for Therapeutic Genetics with ARPA-H funding
The Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory launched a Center for Therapeutic Genetics aimed at developing gene therapies for rare diseases while standardizing protocols to address regulatory and health-system friction. The center is working toward treating its first patient within three years. The initiative is supported by a $34.5 million ARPA-H grant awarded earlier this month to a Broad-led coalition, with early work centered on a gene-editing platform for rare pediatric epilepsies, including alternating hemiplegia of childhood (ATP1A3) and Dravet syndrome (SCN1A). The partners also plan to expand to additional indications such as liver disease. Program leaders positioned the strategy as shifting bespoke, patient-by-patient development toward repeatable therapeutic “procedures,” intended to improve access and reduce the need for separate regulatory pathways per use case.
-
Sickle cell setbacks reshape commercial positioning at Agios
Agios Pharmaceuticals said it is discontinuing tebapivat, its next-generation oral pyruvate kinase activator, after Phase 2 data in sickle cell disease failed to demonstrate the differentiated profile needed for continued development. Agios characterized the drug as not meeting differentiation expectations, ending what was framed as the company’s primary opportunity to distinguish its enzyme-activation strategy. The decision intensifies competitive pressure at Novo Nordisk, which is advancing and has recently reported positive Phase 3 results for its own sickle cell program in this therapeutic space. Within Agios, tebapivat’s drop redirects attention to Pyrukynd (mitapivat), the company’s earlier approved enzyme activator. Agios’ earlier challenges in sickle cell underscore how difficult it has been for developers to translate incremental pharmacology into clinically meaningful differentiation in this indication.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.